Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Lublin – page 21

809 clinical trials in Lublin, Poland across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Lublin at a glance
809
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

809 trials in Lublin

Open in trial search

Chronic lymphocytic leukaemia

Recruiting

Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Acute myeloid leukaemia

Recruiting

Study on Personalized Treatment for Acute Myeloid Leukemia Using Cladribine, Daunorubicin, Cytarabine, and Drug Combinations for Specific Patient Groups

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Medical University Of Lodz

Colitis ulcerative

Recruiting

Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Infliximab
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Myelofibrosis

Recruiting

Study for Myelofibrosis Patients Using Ruxolitinib or Ruxolitinib with Other Cancer Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Seizure

Recruiting

Study on the Safety of Alprazolam for Treating Long Seizures in Patients Aged 12 and Older

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alprazolam
  • Sponsor:UCB Biopharma

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mk-1084
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Recruiting

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Psoriasis

Recruiting

Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:Sun Pharmaceutical Industries Limited

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Lublin

What the registry says about research in the country

01 Respiratory Health Research

Innovative clinical trials focusing on respiratory viral infections and preventive vaccines. Studies include investigations of RSV, human metapneumovirus, and influenza vaccines for older adults, alongside research on pneumococcal infections in children.

  • RSV and hMPV Prevention
  • Influenza Vaccine Development
  • COPD Treatment Studies

Current research emphasizes vaccine efficacy and immune response in vulnerable populations.

02 Dermatological Studies

Comprehensive research into dermatological conditions, with particular focus on psoriasis treatments. Multiple trials evaluating new therapeutic approaches for plaque psoriasis and genital psoriasis.

  • Plaque Psoriasis Treatments
  • Genital Psoriasis Therapy
  • Lichen Sclerosus Studies

Emphasis on developing targeted therapies for moderate to severe cases.

03 Chronic Disease Management

Advanced research into various chronic conditions, including Parkinson's disease, inflammatory bowel diseases, and cardiovascular conditions. Studies focus on innovative treatments and disease management approaches.

  • Heart Failure Prevention
  • Autoimmune Conditions
  • Neurological Disorders

Trials aim to improve patient outcomes through novel therapeutic interventions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.